Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC-K76 in Combination With Endocrine Therapy in mHSPC
NCT07389174Phase 1Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LC-K76 in prostate cancer (PCa) (4 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Incidence of Adverse Events. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
LC-K76
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07389174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389174.